Pieris strengthens its management, as it prepares for the clinical development of PRS-050 cancer therapy
The appointment of Dr Angelika Stern at Pieris coincides with continued progress of the Company's Anticalin® development programs towards the clinic. PRS-050, Pieris' most advanced program addressing the modulation of VEGF for the treatment of cancer, is currently being prepared for a Phase I study in patients with advanced malignancies. Projected to start in 2009, the study aims to assess the safety, pharmacokinetics and immunogenicity of a half-life extended version of the PRS-050 Anticalin®, as well as examining its biological activity.
Dr Stern has considerable experience in the clinical development of biologics in the pharmaceutical industry, specifically Phase I - III development and registration of GM-CSF (Leucomax®) at Novartis in cooperation with Schering-Plough and subsequently as Medical Director for Neupogen® at F. Hoffmann-La Roche. Dr Stern co-founded Hesperion Ltd, a Swiss based international CRO, where she advised emerging biotech companies on development strategy issues.
Most read news
Topics
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.